While the aberrant EGFR expression in that study was not a downregulation of wild-type EGFR, rather expression of a common glioblastoma mutation (EGFRvIII), it supports the idea that specific cohorts of GBM patients may benefit from combined EGFR-targeting and TMZ therapy. Here, EGFR is linked to glioblastoma.